{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:38:24Z","timestamp":1792471104854,"version":"4.5.0"},"reference-count":57,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG072978"],"award-info":[{"award-number":["P30 AG072978"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Plasma p\u2010Tau217 leaves 30%\u201350% of patients in an indeterminate \u201cgray zone\u201d often requiring A\u03b2\u2010PET. We developed GRAD (Gatekeeper\u2010Reflex for Alzheimer's Disease), a two\u2010stage A\u03b2\u2010positivity prediction model to improve classification while reserving A\u03b2\u2010PET for residual uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>GRAD was developed in 145 cognitively impaired ADNI participants and externally validated in 1644 cognitively unimpaired A4\/LEARN participants. Stage 1 used p\u2010Tau217 alone; probabilities between 0.25 and 0.75 were considered indeterminate. Stage 2 used L2\u2010regularized logistic regression combining plasma\u2010biomarkers, genetic and demographic features. A\u03b2\u2010PET served as the reference standard (ADNI florbetapir SUVR &gt;\u20091.11; A4 Centiloid\u2009\u2265\u200920).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Full model AUC was 0.915 (95% CI, 0.859\u20130.961) internally and 0.879 (95% CI, 0.861\u20130.895) externally. In the external gray zone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009630), Stage 2 improved discrimination over p\u2010Tau217 alone (AUC 0.793 vs. 0.719;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), increased correct classification without PET from 41.4% to 56.2%, and reduced PET referral from 35.9% to 24.3%. In the p\u2010Tau181 subset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009256), Stage 2 outperformed p\u2010Tau181 (AUC 0.799 vs. 0.597;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Overall, 89.0% of ADNI and 90.7% of A4\/LEARN participants were classified without PET; modeled testing costs were 44%\u201352% lower than p\u2010Tau217 screening with PET confirmation of the gray zone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Reflex multimarker testing improves indeterminate p\u2010Tau217 classification while retaining A\u03b2\u2010PET for residual uncertainty. GRAD may reduce PET use and testing costs in memory\u2010clinic triage, prevention\u2010trial enrichment, and disease\u2010modifying therapy workup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70560","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:41:38Z","timestamp":1792467698000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Two\u2010Stage Plasma Biomarker Algorithm Reduces Amyloid\n                    <scp>PET<\/scp>\n                    Use and the p\u2010Tau217 Gray Zone"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2796-1436","authenticated-orcid":false,"given":"Harthik","family":"Parankusham","sequence":"first","affiliation":[{"name":"Department of Physiology and Neurobiology, UConn Computational Biology Core University of Connecticut  Storrs Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-5829","authenticated-orcid":false,"given":"Casey","family":"Vanderlip","sequence":"additional","affiliation":[{"name":"Department of Neurobiology and Behavior University of California Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-7700","authenticated-orcid":false,"given":"Colin","family":"Birkenbihl","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eashwar","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cell Biology University of Connecticut  Storrs Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizobam","family":"Ugboaja","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, Yale New Haven Health  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Budson","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System  Boston Massachusetts USA"},{"name":"Alzheimer's Disease Research Center Boston University Chobanian and Avedisian School of Medicine  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Frank","sequence":"additional","affiliation":[{"name":"VA Boston Healthcare System  Boston Massachusetts USA"},{"name":"Alzheimer's Disease Research Center Boston University Chobanian and Avedisian School of Medicine  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer's Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack C. R.","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA\u2010AA Research Framework: Toward a Biological Definition of Alzheimer's Disease","volume":"14","author":"Jack C. R.","year":"2018","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70535","article-title":"Alzheimer's Association Clinical Practice Guideline on the Use of Blood\u2010Based Biomarkers in the Diagnostic Workup of Suspected Alzheimer's Disease Within Specialized Care Settings","volume":"21","author":"Palmqvist S.","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho\u2010tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist S.","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton N. J.","year":"2024","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly Accurate Blood Test for Alzheimer's Disease Is Similar or Superior to Clinical Cerebrospinal Fluid Tests","volume":"30","author":"Barth\u00e9lemy N. R.","year":"2024","journal-title":"Nature Medicine"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma Phospho\u2010tau217 for Alzheimer's Disease Diagnosis in Primary and Secondary Care Using a Fully Automated Platform","volume":"31","author":"Palmqvist S.","year":"2025","journal-title":"Nature Medicine"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/brain\/awae346","article-title":"A Comprehensive Head\u2010To\u2010Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests","volume":"148","author":"Warmenhoven N.","year":"2025","journal-title":"Brain"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105046","article-title":"Comparison of Two Plasma p\u2010tau217 Assays to Detect and Monitor Alzheimer's Pathology","volume":"102","author":"Therriault J.","year":"2024","journal-title":"eBioMedicine"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and Staging of Alzheimer's Disease by Plasma pTau217 on a High Throughput Immunoassay Platform","volume":"109","author":"Feizpour A.","year":"2024","journal-title":"eBioMedicine"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2025.3217","article-title":"Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease","volume":"82","author":"Salvad\u00f3 G.","year":"2025","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_13_1","first-page":"1797","article-title":"Plasma p\u2010tau231 and p\u2010tau217 as State Markers of Amyloid\u2010\u03b2 Pathology in Preclinical Alzheimer's Disease","volume":"28","author":"Mil\u00e0\u2010Alom\u00e0 M.","year":"2022","journal-title":"Nature Medicine"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13195-026-02080-x","article-title":"Plasma p\u2010tau217, p\u2010tau181, and A\u03b242 Predict Amyloid PET Positivity in Cognitively Unimpaired Adults","volume":"18","author":"Bao R.","year":"2026","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies","volume":"81","author":"Mattsson\u2010Carlgren N.","year":"2024","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70113","article-title":"Cut\u2010Points and Gray Zones: The Challenges of Integrating Alzheimer's Disease Plasma Biomarkers Into Clinical Practice","volume":"21","author":"Hazan J.","year":"2025","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A Two\u2010Step Workflow Based on Plasma p\u2010tau217 to Screen for Amyloid \u03b2 Positivity With Further Confirmatory Testing Only in Uncertain Cases","volume":"3","author":"Brum W. S.","year":"2023","journal-title":"Nature Aging"},{"key":"e_1_2_12_18_1","article-title":"Refining Alzheimer's Disease Biological Diagnosis With Plasma Biomarkers: Resolving p\u2010tau217 \u201cGray Zone\u201d With p\u2010tau181 Integration","volume":"18","author":"Giacomucci G.","year":"2026","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood Phosphorylated Tau 181 as a Biomarker for Alzheimer's Disease: A Diagnostic Performance and Prediction Modelling Study Using Data From Four Prospective Cohorts","volume":"19","author":"Karikari T. K.","year":"2020","journal-title":"Lancet Neurology"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic Performance and Prediction of Clinical Progression of Plasma Phospho\u2010tau181 in the Alzheimer's Disease Neuroimaging Initiative","volume":"26","author":"Karikari T. K.","year":"2021","journal-title":"Molecular Psychiatry"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic Value of Plasma Phosphorylated tau181 in Alzheimer's Disease and Frontotemporal Lobar Degeneration","volume":"26","author":"Thijssen E. H.","year":"2020","journal-title":"Nature Medicine"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","article-title":"Head\u2010To\u2010Head Study of Diagnostic Accuracy of Plasma and Cerebrospinal Fluid p\u2010tau217 Versus p\u2010tau181 and p\u2010tau231 in a Memory Clinic Cohort","volume":"271","author":"Mendes A. J.","year":"2024","journal-title":"Journal of Neurology"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and Phospho\u2010tau217 Concentration Ratios Increase the Accuracy of Amyloid PET Classification in Preclinical Alzheimer's Disease","volume":"20","author":"Rissman R. A.","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105741","article-title":"A Plasma Biomarker Panel for Detecting Early Amyloid\u2010\u03b2 Accumulation and Its Changes in Middle\u2010Aged Cognitively Unimpaired Individuals at Risk for Alzheimer's Disease","volume":"116","author":"Gonz\u00e1lez\u2010Escalante A.","year":"2025","journal-title":"eBioMedicine"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14536","article-title":"Plasma p\u2010tau217 and p\u2010tau217\/A\u03b21\u201042 Are Effective Biomarkers for Identifying CSF\u2010 and PET Imaging\u2010Diagnosed Alzheimer's Disease: Insights for Research and Clinical Practice","volume":"21","author":"Zhong X.","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70038","article-title":"Diagnostic Accuracy of Plasma p\u2010tau217\/A\u03b242 for Alzheimer's Disease in Clinical and Community Cohorts","volume":"21","author":"Wang J.","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 Ratio, p\u2010tau181, GFAP, and NfL Across the Alzheimer's Disease Continuum: A Cross\u2010Sectional and Longitudinal Study in the AIBL Cohort","volume":"19","author":"Chatterjee P.","year":"2023","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70987","article-title":"Plasma p\u2010tau217, GFAP, and NfL as Biomarkers for Alzheimer's Disease: Role in Disease Stratification, Pathological Progression, and Cognitive Decline","volume":"21","author":"Pan F. F.","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00942-0","article-title":"The Accuracy and Robustness of Plasma Biomarker Models for Amyloid PET Positivity","volume":"14","author":"Benedet A. L.","year":"2022","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinbiochem.2022.03.003","article-title":"Reflex and Reflective Laboratory Interventions for Adding Value to Test Results; an Integral Part of Laboratory Stewardship","volume":"105","author":"Elnenaei M. O.","year":"2022","journal-title":"Clinical Biochemistry"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/cclm-2019-0625","article-title":"Reflex TSH Strategy: The Good, the Bad and the Ugly","volume":"58","author":"Plebani M.","year":"2019","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing Positron Emission Tomography Imaging and Cerebrospinal Fluid Measurements of \u03b2\u2010Amyloid","volume":"74","author":"Landau S. M.","year":"2013","journal-title":"Annals of Neurology"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","article-title":"Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes","volume":"72","author":"Schreiber S.","year":"2015","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Amyloid Negativity in Patients With Clinically Diagnosed Alzheimer Disease and MCI","volume":"86","author":"Landau S. M.","year":"2016","journal-title":"Neurology"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"P215","DOI":"10.1016\/j.jalz.2018.06.2337","article-title":"O1\u201002\u201002: The Anti\u2010Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study: Report of Screening Data Results","volume":"14","author":"Sperling R.","year":"2018","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals","volume":"77","author":"Sperling R. A.","year":"2020","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/acn3.51048","article-title":"The A4 Study: \u03b2\u2010Amyloid and Cognition in 4432 Cognitively Unimpaired Adults","volume":"7","author":"Insel P. S.","year":"2020","journal-title":"Annals of Clinical Translational Neurology"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.14283\/jpad.2024.122","article-title":"Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data From the A4 and LEARN Studies","volume":"11","author":"Sperling R. A.","year":"2024","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET","volume":"11","author":"Klunk W. E.","year":"2015","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical Characterization","volume":"74","author":"Petersen R. C.","year":"2010","journal-title":"Neurology"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.14283\/jpad.2024.134","article-title":"Longitudinal Phospho\u2010tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease","volume":"11","author":"Rissman R. A.","year":"2024","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/brain\/awac128","article-title":"Plasma Biomarkers and Genetics in the Diagnosis and Prediction of Alzheimer's Disease","volume":"146","author":"Stevenson\u2010Hoare J.","year":"2023","journal-title":"Brain"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies","volume":"351","author":"Bossuyt P. M.","year":"2015","journal-title":"BMJ"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the Areas Under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach","volume":"44","author":"DeLong E. R.","year":"1988","journal-title":"Biometrics"},{"key":"e_1_2_12_45_1","volume-title":"Clinical Laboratory Fee Schedule and Physician Fee Schedule, Calendar Year 2024","author":"Centers for Medicare and Medicaid Services","year":"2024"},{"key":"e_1_2_12_46_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100474","article-title":"Cost\u2010Effectiveness Analysis of Blood\u2010Based Biomarker Testing in the Diagnosis of Alzheimer's Disease Pathology","volume":"13","author":"Li Y.","year":"2026","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00406-022-01439-z","article-title":"Cost\u2010Effectiveness of Alzheimer's Disease CSF Biomarkers and Amyloid\u2010PET in Early\u2010Onset Cognitive Impairment Diagnosis","volume":"273","author":"Contador J.","year":"2023","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41591-025-03605-x","article-title":"Blood\u2010Based Biomarkers of Alzheimer's Disease and Incident Dementia in the Community","volume":"31","author":"Grande G.","year":"2025","journal-title":"Nature Medicine"},{"key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting Amyloid PET and Tau PET Stages With Plasma Biomarkers","volume":"146","author":"Jack C. R.","year":"2023","journal-title":"Brain"},{"key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR\u2010tau243 Biomarker Identifies Tau Tangle Pathology in Alzheimer's Disease","volume":"31","author":"Horie K.","year":"2025","journal-title":"Nature Medicine"},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain\u2010Derived Tau: A Novel Blood\u2010Based Biomarker for Alzheimer's Disease\u2010Type Neurodegeneration","volume":"146","author":"Gonzalez\u2010Ortiz F.","year":"2023","journal-title":"Brain"},{"key":"e_1_2_12_52_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25805","article-title":"Rural\u2010Urban Disparities in Diagnosis of Early\u2010Onset Dementia","volume":"5","author":"Xu W. Y.","year":"2022","journal-title":"JAMA Network Open"},{"key":"e_1_2_12_53_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100305","article-title":"Systematic Review and Meta\u2010Analysis of Rural\u2010Urban Disparities in Alzheimer's Disease and Related Dementias","volume":"12","author":"Mollalo A.","year":"2025","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"e_1_2_12_54_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14297","article-title":"The Taiwan\u2010ADNI Workflow Toward Integrating Plasma p\u2010tau217 Into Prediction Models for the Risk of Alzheimer's Disease and Tau Burden","volume":"21","author":"Huang K. L.","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_55_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14565","article-title":"Cross\u2010Cultural Validation of Plasma p\u2010tau217 and p\u2010tau181 as Precision Biomarkers for Amyloid PET Positivity: An East Asian Study in Taiwan and Korea","volume":"21","author":"Lin Y. S.","year":"2025","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_56_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210287","article-title":"Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma p\u2010tau217 Concentrations","volume":"104","author":"Bornhorst J. A.","year":"2025","journal-title":"Neurology"},{"key":"e_1_2_12_57_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2025.5530","article-title":"Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia","volume":"83","author":"Yun J.","year":"2026","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_58_1","article-title":"Hepatic and Renal Function Impact Concentrations of Plasma Biomarkers of Neuropathology","volume":"14","author":"Berry K.","year":"2022","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:41:47Z","timestamp":1792467707000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":57,"alternative-id":["10.1002\/acn3.70560"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70560","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"2026-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acn3.70560"}}